Functional characterization of a novel somatic oncogenic mutation of PIK3CB

Class I phosphoinositide 3-kinase (PI3K) enzymes have attracted considerable attention as drug targets in cancer therapy over the last 20 years. The signaling pathway triggered by class I PI3Ks is dysregulated in a range of tumor types, impacting cell proliferation, survival and apoptosis. Frequent...

Descripción completa

Detalles Bibliográficos
Autores principales: Whale, Andrew D, Colman, Lucy, Lensun, Letitia, Rogers, Helen L, Shuttleworth, Stephen J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5740215/
https://www.ncbi.nlm.nih.gov/pubmed/29279775
http://dx.doi.org/10.1038/sigtrans.2017.63

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5740215/
https://www.ncbi.nlm.nih.gov/pubmed/29279775
http://dx.doi.org/10.1038/sigtrans.2017.63

Ejemplares similares